|
1
|
Cardoso PG, Macedo GC, Azevedo V and
Oliveira SC: Brucella spp noncanonical LPS: structure,
biosynthesis and interaction with host immune system. Microb Cell
Fact. 5:132006. View Article : Google Scholar
|
|
2
|
Rambow-Larsen AA, Petersen EM, Gourley CR
and Splitter GA: Brucella regulators: self-control in hostil
environment. Trends Microbiol. 17:371–377. 2009. View Article : Google Scholar
|
|
3
|
Al-Tawfiq JA: Therapeutic options for
human brucellosis. Expert Rev Anti Infect Ther. 6:109–120. 2008.
View Article : Google Scholar
|
|
4
|
Pappas G, Papadimitrious P, Akritidis N,
Christou L and Tsianos E: The new global map of human brucellosis.
Lancet Infect Dis. 6:91–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa
AM and Rice-Ficht AC: Brucellosis: the case for live, attenuated
vaccines. Vaccine. 27:D40–D43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spink WW, Hall JW, Finstad J and Mallet E:
Immunization with viable Brucella organisms. Results of a
safety test in humans. B World Health Organ. 26:409–419. 1962.
|
|
7
|
Perkins SD, Smither SJ and Atkins HS:
Towards a Brucella vaccine for humans. FEMS Microbiol Rev.
34:379–394. 2010.
|
|
8
|
Monreal D, Grilló MJ, González D, Marín
CM, De Miguel MJ, López-Goni I, Blasco JM, Cloeckaert A and Moriyón
I: Characterization of Brucella abortus O-polysaccharide and
core lipopolysaccharide mutant and demonstration that a complete
core is required for rough vaccines to be efficient against
Brucella abortus and Brucella ovis in the mouse
model. Infect Immun. 71:3261–3271. 2003.
|
|
9
|
Fugier E, Pappas G and Gorvel JP:
Virulence factors in brucellosis: implications for
aetiopathogenesis and treatment. Expert Rev Mol Med. 9:1–10. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bundle DR, Cherwonogrodzky JW, Gidney MA,
Meikle PJ, Perry MB and Peters T: Definition of Brucella A and M
epitopes by monoclonal typing reagents and synthetic
oligosaccharides. Infect Immun. 57:2829–2836. 1989.PubMed/NCBI
|
|
11
|
Weynants V, Gilson D, Cloeckaert A, Tibor
A, Denoel PA, Godfroid F, Limet JN and Letesson JJ:
Characterization of smooth lipopolysaccharides and
O-polysaccharides of Brucella species by competition binding
assays with monoclonal antibodies. Infect Immun. 65:1939–1943.
1997.PubMed/NCBI
|
|
12
|
Ugalde JE, Comerci DJ, Leguizamón MS and
Ugalde RA: Evaluation of Brucella abortus phosphoglucomutase
(pgm) mutant as a new live rough-phenotype vaccine. Infect Immun.
71:6264–6269. 2003.PubMed/NCBI
|
|
13
|
Lapaque N, Moriyon I, Moreno E and Gorvel
JP: Brucella lipopolysaccharide acts as a virulence factor. Curr
Opin Microbiol. 8:60–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenschenk FC, Houle JJ and Hoffmann EM:
Serum sensitivity of field isolates and laboratory strains of
Brucella abortus. Am J Vet Res. 56:1592–1598.
1995.PubMed/NCBI
|
|
15
|
Velasco J, Bengoechae JA, Brandenberg K,
Lindner B, Seydel U, Gonzalez D, Zahringer U, Moreno E and Moriyon
I: Brucella abortus and its closest phylogenetic relative,
ochrobacterum spp, differ in outer membrane permeability and
cationic peptide resistance. Infect Immun. 68:3210–3218. 2000.
View Article : Google Scholar
|
|
16
|
Lapaque N, Forquet F, de Chastellier C,
Mishal Z, Jolly G, Moreno E, Moriyon I, Heuser JE, He HT and Gorvel
JP: Characterization of Brucella abortus lipopolysaccharide
macrodomains as mega rafts. Cell Microbiol. 8:197–206. 2006.
|
|
17
|
Porte F, Naroeni A, Ouahrani-Bettache S
and Liautard JP: Role of the Brucella suis
lipopolysaccharide O antigen in phagosomal genesis and in
inhibition of phagosome-lysosome fusion in murine macrophages.
Infect Immun. 74:1481–1490. 2003.
|
|
18
|
Fernandez-Prada CM, Zelazowska EB,
Nikolich M, Hadfield TL, Roop RM, Robertson GL and Hoover DL:
Interactions between Brucella melitensis and human
phagocytes: bacterial surface O-polysaccharide inhibits
phagocytosis, bacterial killing and subsequent host cell apoptosis.
Infect Immun. 71:2110–2119. 2003.
|
|
19
|
Jiménez de Bagüés MP, Terraza A, Gross A
and Dornand J: Different responses of macrophages to smooth and
rough Brucella spp: relationship to virulence. Infect Immun.
72:2429–2433. 2004.PubMed/NCBI
|
|
20
|
Moriyón I, Grilló MJ, Monreal D, González
D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E and Blasco JM:
Rough vaccines in animals brucellosis: structural and genetic basis
and present status. Vet Res. 35:1–38. 2004.PubMed/NCBI
|
|
21
|
Adone R, Ciuchini F, Marianelli C,
Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G
and Pasquali P: Protective properties of rifampin-resistant rough
mutants of Brucella melitensis. Infect Immun. 73:4198–4204.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haag AF, Myka KK, Arnold MF,
Caro–Hernández P and Ferguson GP: Importance of lipopolysaccharide
and cyclic β-1,2-glucans in Brucella-mammalian infections.
Int J Microbiol. 2010:1245092010.
|
|
23
|
Cloeckaert A, Grayon M, Verger JM,
Letesson JJ and Godfroid F: Conservation of seven genes involved in
the biosynthesis of the lipopolysaccharide O-side chain in
Brucella spp. Res Microbiol. 151:209–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Godfroid F, Cloeckaert A, Taminiau B,
Danese I, Tibor A, de Bolle X, Mertens P and Letesson JJ: Genetic
organization of the lipopolysaccharide O-antigen biosynthesis
region of Brucella melitensis 16M (wbk). Res Microbiol.
151:655–668. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
González D, Grilló MJ, De Miguel MJ, Ali
T, Arce-Gorvel V, Delrue RM, Conde-Alvarez R, Muñoz P, López-Goñi
I, Iriarte M, Marín CM, Weintraub A, Widmalm G, Zygmunt M, Letesson
JJ, Gorvel JP, Blasco JM and Moriyón I: Brucellosis vaccines:
assessment of Brucella melitensis lipopolysaccharide rough
mutants defective in core and O-polysaccharide synthesis and
export. PLoS One. 3:e27602008.
|
|
26
|
Allen CA, Adams LG and Ficht TA:
Transposon-derived Brucella abortus rough mutants are
attenuated and exhibit reduced intracellular survival. Infect
Immun. 66:1008–1016. 1998.PubMed/NCBI
|
|
27
|
Ried JL and Collmer A: An nptI-sacB-sacR
cartridge for constructing directed, unmarked mutations in
gram-negative bacteria by marker exchange-eviction mutagenesis.
Gene. 57:239–246. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Christian RHR and Chris W:
Lipopolysaccharide endotoxins. Annu Rev Biochem. 71:635–700. 2002.
View Article : Google Scholar
|
|
29
|
Grilló MJ, Blasco JM, Gorvel JP, Moriyón I
and Moreno E: What have we learned from brucellosis in the mouse
model? Vet Res. 43:292012.PubMed/NCBI
|
|
30
|
Skyberg JA, Thornburg T, Rollins M, Huarte
E, Jutila MA and Pascual DW: Murine and bovine γδT cells enhance
innate immunity against Brucella abortus infections. PLoS
One. 6:e219782012.
|
|
31
|
Li X and He Y: Caspase-2-dependent
dendritic cell death, maturation and priming of t cells in response
to Brucella abortus infection. PLoS One. 7:e435122012.
View Article : Google Scholar : PubMed/NCBI
|
